Summary:
The efficacy of mobilizing peripheral blood progenitor cells (PBPC) with continuous intravenous (c.i.v.) administration of rhG-CSF was randomly compared to subcutaneous (s.c.) administration, in 15 normal donors in each arm of the study for 6 days. The percentage and absolute numbers of CD34+ cells in the c.i.v. and s.c. groups increased maximally at day 3 and 5, respectively, when compared with the steady-state (day 0) level. Peak CD34+ cell levels were achieved on day 3 in the c.i.v. group, with more rapid results than in the s.c. group (49.3/μl vs 35.9/μl, P=0.043). Plasma rhG-CSF levels declined progressively during mobilization in each group as the WBC increased. The serum level of rhG-CSF did not correlate with CD34+ cell counts in the peripheral blood. Toxicity profiles in the c.i.v. and s.c. groups were similar. Each regimen was effective in successfully mobilizing the target CD34 cell number.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kröger N, Renges H, Kruger W et al. A randomized comparison of once vs twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761–765.
de la Rubia J, Arbona C, de Arriba F et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002; 42: 4–9.
Anderlini P, Donato M, Lauppe MJ et al. A comparative study of once-daily vs twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 2000; 109: 770–772.
Martinez C, Urbano-Ispizua A, Marin P et al. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant 1999; 24: 1273–1278.
Engelhardt BM, Bertz H, Afting M et al. High-vs standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34+ immunoselection. J Clin Oncol 1999; 17: 2160–2172.
Watts MJ, Addison I, Long SG et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997; 98: 474–479.
de Haas M, Kerst JM, ven der Schoot CE et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994; 84: 3885–3894.
van der Auwera P, Platzer E, Xu ZX et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF Mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol 2001; 66: 245–251.
Lee S, Im SA, Yoo ES et al. Mobilization kinetics of CD34+ cells in association with modulation of CD44 and CD31 expression during continuous intravenous administration of G-CSF in normal donors. Stem Cells 2000; 18: 281–286.
Seong C, Durett A, Mirza N et al. Mobilization kinetics of CD34+/Thy-1dim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors. Transfusion 1997; 37: 406–410.
Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213–226.
Miflin G, Charley C, Stainer C et al. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol 1996; 95: 345–348.
de Fabritiis P, Iori AP, Mengarelli A et al. CD34+cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion 2001; 41: 190–195.
Papayannopoulou T, Priestley GV, Nakamoto B . Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998; 91: 2231–2239.
Craddock CF, Nakamoto B, Andrews RG et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997; 90: 4779–4788.
Papayannopoulou T . Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. Semin Hematol 2000; 37: 11–18.
Liles W, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730.
Aiuti A, Webb IJ, Bleul C et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to the peripheral blood. J Exp Med 1997; 185: 111–120.
Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and upregulating CXCR4. Nat Immunol 2002; 3: 687–694.
Peled A, Kollet O, Ponomaryov T et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000; 95: 3289–3296.
Laterveer L, Lindley IJ, Hamilton MS et al. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood 1995; 85: 2269–2275.
Fibbe WE, Pruijt JF, van Kooyk Y et al. The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem cell mobilization. Semin Hematol 2000; 37: 19–24.
Levesque JP, Takamatsu Y, Nilsson SK et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289–1297.
Matsuzaki G, Li XY, Ohyama Y et al. Kinetics of serum granulocyte-colony stimulating factor (G-CSF) concentration and G-CSF receptor expression during G-CSF treatment of cyclophosphamide-treated mice. Int J Immunopharmacol 1996; 18: 363–369.
Yano T, Katayama Y, Sunami K et al. G-CSF-induced mobilization of peripheral blood stem cells for allografting: comparative study of daily single vs divided dose of G-CSF. Int J Hematol 1997; 66: 169–178.
Liu F, Poursine-Laurent J, Link DC . Expression of the G-CSF receptor on hematopoietic progenitor cells in not required for their mobilization by G-CSF. Blood 2000; 95: 3025–3031.
Acknowledgements
We thank H-A Koo and S-M Chu for editorial assistance. This work was supported by Grant (‘the 2005 University Specialization Grant’) from the Ministry of Education & Human Resources Development.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, KE., Mun, Y., Nam, SH. et al. A prospective randomized study on the mobilization of CD34+ cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors. Bone Marrow Transplant 36, 1027–1031 (2005). https://doi.org/10.1038/sj.bmt.1705186
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705186
